Search clinical trials for: Endothelin Receptor B inhibitor BQ788

Total 6901 results

MelCure SA
Universitaire Ziekenhuizen KU Leuven; University of Bern; California Institute...

Terminated

Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma

Melanoma
University of Southern Denmark
The University of Texas at Arlington

Active, not recruiting

Insulin Stimulated Vasodilation in Patients With Type 2 Diabetes

Type2 Diabetes

Denmark
Actelion

Withdrawn

Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis (MUSIC OL)

Idiopathic Pulmonary Fibrosis
Actelion

Completed

A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult Participants

Healthy

Belgium
Actelion

Terminated

A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain (ORCHESTRA)

Pulmonary Arterial Hypertension

Spain, France, Italy
Boston University
Actelion

Terminated

Macitentan in Pulmonary Hypertension of Sickle Cell Disease (MENSCH)

Sickle Cell Disease | Pulmonary Hypertension

United States
Actelion

Completed

REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension (REPAIR)

Pulmonary Arterial Hypertension

United States, Israel, France, Netherlands, Malaysia, Germany, Australia, United Kingdom, Hong Kong, Italy, Russian Federation, Singapore
University of California, Los Angeles
American Heart Association; Janssen, LP

Completed

Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)

Cardiac Allograft Vasculopathy

United States
Actelion

Completed

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension (SERAPHIN OL)

Pulmonary Arterial Hypertension

United States, United Kingdom, Taiwan, Finland, Canada, Belarus, Belgium, Argentina, Australia, China, Colombia, Croatia, Germany, Hong Kong, India, Israel, Italy, Malaysia, Netherlands, Poland, Russian Federation, South Africa, Tha... and more
Actelion

Terminated

Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument (SYMPHONYext)

Pulmonary Arterial Hypertension

United States
Janssen Pharmaceutical K.K.

Recruiting

A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Japan
Assistance Publique - Hôpitaux de Paris
Janssen, LP

Recruiting

Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (IMPACT-CTEPH)

Chronic Disease | Inoperable Disease | Thromboembolic Pulmonary Hypertension

France
Actelion

Completed

A Study of Two Macitentan Pediatric Formulations in Healthy Adult Participants

Healthy

Belgium
University of Giessen
Philipps University Marburg Medical Center

Recruiting

(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment) (RightHeartIII)

Pulmonary Arterial Hypertension (PAH)

Germany
Actelion
Henry Ford Health System; Covance; Medidata Solutions; Almac Clinical Technologies and other collaborators

Terminated

An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients. (RUBATO OL)

Congenital Heart Disease With Fontan Circulation

United Kingdom, Taiwan, France, Poland, China, Australia, Czechia, Canada, United States, Denmark, New Zealand
Actelion

Completed

Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (MERIT-1)

Chronic Thromboembolic Pulmonary Hypertension

United Kingdom, Belgium, Ukraine, Germany, Switzerland, Hungary, China, Korea, Republic of, Mexico, Czechia, France, Lithuania, Poland, Russian Federation, Thailand, Turkey
Franz Rischard, DO
University of Pittsburgh; National Jewish Health

Unknown

CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH (CRUSADE)

Pulmonary Hypertension | Interstitial Lung Disease | Scleroderma

United States
Actelion

Completed

Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

Pulmonary Arterial Hypertension

United States
Actelion

Completed

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease (SERENADE)

Heart Failure With Preserved Ejection Fraction

United States, Spain, United Kingdom, Poland, Germany, Israel, Austria, Czechia, Russian Federation, Denmark, Bulgaria, Hungary, France, Argentina, Brazil, Romania, Sweden
Actelion

Completed

Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH

Pulmonary Arterial Hypertension

Spain, France, Italy
Actelion

Recruiting

A Study of Macitentan in Healthy Chinese Adult Male Participants

Healthy

China
University of Maryland, Baltimore

Withdrawn

Macitentan to Prevent PRVO (MAC-PRO)

Pulmonary Embolism

United States
Actelion

Completed

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects (RUBATO)

Congenital Heart Disease

United States, United Kingdom, Taiwan, Germany, France, Poland, China, Australia, Czechia, Canada, Denmark, New Zealand
Actelion

Completed

Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension (SERAPHIN)

Pulmonary Arterial Hypertension

United States, United Kingdom, Belarus, Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, China, Colombia, Croatia, France, Germany, Hong Kong, Hungary, India, Israel, Italy, Malaysia, Mexico, Netherlands, Norway, Peru, Poland and more
Actelion

Completed

PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial (PORTICO)

Portopulmonary Hypertension

United States, France, Germany, United Kingdom, Brazil, Czechia, Spain
Actelion

Terminated

Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA) (OPTIMA)

Pulmonary Arterial Hypertension

France
Actelion

Terminated

A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension (MACiTEPH)

Chronic Thromboembolic Pulmonary Hypertension

United States, Germany, Japan, Korea, Republic of, Taiwan, Canada, United Kingdom, China, Austria, Italy, Bulgaria, Turkey, Spain, Thailand, Israel, Ukraine, Hungary, Mexico, Czechia, Russian Federation, France, Saudi Arabia, Singapore and more
Actelion

Completed

OPsumit USers Registry (OPUS)

Pulmonary Arterial Hypertension

United States, Puerto Rico
Actelion

Completed

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (TRITON)

Pulmonary Arterial Hypertension

United States, Spain, Denmark, Canada, Germany, United Kingdom, Belgium, Austria, Netherlands, Australia, France, Ireland, Sweden, Italy, Switzerland
Actelion

Completed

A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies. (UMBRELLA)

Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary Hypertension

Belgium, France, Poland, Russian Federation, Belarus, Turkey, Ukraine
University of California, Los Angeles

Withdrawn

Macitentan in the Treatment of Organ Rejection After Lung Transplantation

Lung Transplant Rejection

United States
Actelion

Completed

Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome (MAESTRO)

Pulmonary Arterial Hypertension

China, Malaysia, United States, Austria, Bulgaria, Chile, France, Germany, Greece, Israel, Mexico, Philippines, Poland, Portugal, Romania, Russian Federation, Serbia, Spain, Turkey, United Kingdom, Vietnam
Actelion

Withdrawn

A Study of Macitentan in Children Below 2 Years of Age

Arterial Hypertension, Pulmonary

Poland, Germany
Actelion

Completed

Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (MERIT-2)

Chronic Thromboembolic Pulmonary Hypertension

Poland, Ukraine, United Kingdom, China, Russian Federation, Belgium, Germany, Thailand, Hungary, France, Lithuania, Czechia, Mexico, Switzerland, Turkey
Actelion

Completed

A Study of Two Macitentan Formulations in Healthy Adult Participants

Healthy

Belgium
Actelion

Completed

Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study (MUSIC)

Idiopathic Pulmonary Fibrosis

United States, Israel, Spain, Australia, France, Canada, Turkey, Germany, Italy, South Africa, Slovenia, Sweden
Actelion

Completed

Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction (MELODY-1)

Pulmonary Hypertension

United States, Austria, Belgium, Canada, Czechia, France, Germany, Israel, Italy, Spain, Switzerland
Actelion

Recruiting

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) (TOMORROW)

Pulmonary Arterial Hypertension

United States, Korea, Republic of, Spain, Malaysia, China, Hungary, Mexico, Poland, Australia, Austria, Brazil, Canada, Colombia, France, Israel, Philippines, Portugal, Russian Federation, South Africa, Thailand, Ukraine, Vietnam, F...
Janssen Research & Development, LLC

Completed

A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants

Healthy

United States
Actelion
EPS Corporation; Imepro Inc.; General Laboratory, BML, Inc.; Mitsubishi Logistics...

Terminated

A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Japan
Actelion

Completed

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients (DUAL-1)

Systemic Sclerosis | Ulcers

Canada, United States, Belarus, Hungary, Croatia, Australia, Denmark, Ukraine, Bulgaria, Chile, Colombia, Czech Republic, Finland, Germany, India, Italy, Poland, Russian Federation
Actelion

Terminated

Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome (MAESTRO-OL)

Pulmonary Arterial Hypertension

China, Malaysia, United States, Austria, Bulgaria, Chile, France, Germany, Greece, Mexico, Philippines, Poland, Portugal, Romania, Russian Federation, Serbia, Spain, United Kingdom, Vietnam
Actelion

Terminated

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients (DUAL-2)

Digital Ulcers

Spain, United States, Argentina, China, Ireland, Colombia, Israel, New Zealand, Germany, Belgium, Portugal, Netherlands, South Africa, Greece, Mexico, Poland, Puerto Rico, Russian Federation, Turkey, Ukraine, United Kingdom
Dr Sudarshan Rajagopal
Actelion

Not yet recruiting

Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH (EPIPHANY)

CTEPH

United States
Actelion

Completed

Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation (SOPRANO)

Pulmonary Hypertension

United States
Actelion

Completed

Clinical Study to Investigate Effect of Macitentan on Riociguat Pharmacokinetics

Healthy Subjects

Germany
Actelion
Chiltern International Ltd.; Medidata Solutions; Frontier Science & Technology... and other collaborators

Terminated

A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease (SERENADE OL)

Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

United States, United Kingdom, Israel, Austria, Russian Federation, Germany, Poland, Denmark, Argentina, Brazil, Bulgaria, France, Hungary, Romania, Sweden
Actelion

Completed

A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects

Healthy Subjects

Germany
Janssen Pharmaceutical K.K.

Completed

A Study of Macitentan, in Healthy Japanese Male Participants

Healthy

Japan
Actelion

Completed

Clinical Study to Investigate the Effect of Macitentan on the Concentrations of Rosuvastatin in the Blood of Healthy Male Subjects

Healthy Subjects

Germany

Search clinical trials for: Endothelin Receptor B inhibitor BQ788

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations